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ABSTRACT  
Background: Low back pain (LBP) is a common disabling condition. Lumbar disc degeneration 
(LDD) may be a contributing factor for LBP. Modic change (MC), a distinct phenotype of LDD, is 
presented as a pathological bone marrow signal change adjacent to vertebral endplate on magnetic 
resonance imaging (MRI). It is strongly associated with LBP and has heritability around 30%. Our 
objective was to identify genetic loci associated with MC using a genome-wide meta-analysis. 
Methods: Presence of MC was evaluated in lumbar MRI in the Northern Finland Birth Cohort 1966 
(N=1182) and TwinsUK (N=647). Genome-wide association analyses were carried out using linear 
regression model. Inverse-variance weighting approach was used in themeta-analysis. 
Results: A locus associated with MC (p<5e-8) was found on chromosome 9 with the lead SNP 
rs1934268 in an intron of the PTPRD gene. It is located in the binding region of BCL11A, SPI1 and 
PBX3 transcription factors. The SNP was nominally associated with LBP in TwinsUK (p = 0.001), 
but not associated in the UK Biobank (p = 0.914). Suggestive signals (p<1e-5) were identified near 
XKR4, SCIN, MGMT, DLG2, ZNF184, and OPRK1. 
Conclusion: PTPRD is a novel candidate gene for MC that may act via the development of cartilage 
or nervous system; further work is needed to define the mechanisms underlying the pathways leading 
to development of MC. This is the first genome-wide meta-analysis of MC and the results pave the 
way for further studies on the genetic factors underlying the various features of spine degeneration 
and LBP.  
 
INTRODUCTION  
Low back pain (LBP) is highly prevalent and disabling musculoskeletal condition throughout the 
world causing significant burden to the society [1]. In Europe, it is estimated to consume as much of 
a country’s GDP as 0.7% - 2.2%. Lumbar disc degeneration (LDD) is likely a risk factor for LBP, 
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based on multiple epidemiologic studies [2-6], even though it is not universally accepted due to the 
presence of confirmed disc pathology among asymptomatic individuals [7] and the presence of LBP 
among patients without LDD [8]. The role of genetic factors in the development of LDD has been 
demonstrated to be significant, with heritability estimates ranging from 64 to 81% [9].  
Modic change (MC), subchondral and vertebral bone marrow change visible on spine magnetic 
resonance (MR) imaging, are reported in 20%-50% of patients with LDD [10-12]. MC can be divided 
into three different types according to T1- and T2-weighted MRIs: type 1 (MC1) (low T1 and high 
T2 signals) indicating an ongoing degeneration, type 2 (MC2) (high T1 and high T2 signals) 
indicating fatty replacement of the bone marrow and type 3 (MC3) (low T1 and low T2 signals) 
indicating bone sclerosis [10-12]. MC can convert from one type to another and also mixed types 
have been identified [11-13]. MC has been strongly associated with LBP (odds ratio, OR = 6.1 (95% 
confidence interval, CI = 2.9–13.1)) and poor reduction of pain (β = −9.79 (95% CI = −16.7 to −2.90)) 
in clinical groups [14,15] and with LBP in general population samples (OR ranging from 1.9 (95% 
CI = 1.2–3.0) to 4.5 (95% CI = 1.7–11.6)) [16]. Like LDD, MC is common with the prevalence of 
MC up to 56% in general population [17,18] and 81% in clinical samples [19,20]. 
The genetic background of MC is largely unknown but the heritability of MC has been estimated in 
the range 16%-43% [21]. Previously, the genetic basis of MC has been studied using candidate gene 
approach and whole exome sequencing. Interleukin-1α (IL1A) and matrix metallopeptidase 3 
(MMP3) were found to be significantly associated with MC (OR = 3.2 (95% CI = 1.2-8.5); OR=2.50 
(95% CI = 1.09–5.71, respectively) [22,23] and variants in mastermind like transcriptional coactivator 
1 (MAML1) and heparan sulfate proteoglycan 2 (HSPG2) genes co-segregated with MC[24]. 
Differential expression of tumor necrosis factor α (TNF-α), ADAM metallopeptidase with 
thrombospondin type 1 motif 5 (ADAMTS5), and NLRP3/caspase-1/interleukin-1β axis has been 
reported in cartilaginous endplate of patients with MC [25,26]. 
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Given that the pathogenic mechanisms underlying MC are unknown but genetic factors do play a 
role, agnostic approaches such as genome-wide association study (GWAS), may provide information 
about underlying genetically-mediated pathways of pathology. Herewith we report the first ever 
GWAS for MC based on the meta-analysis of two population samples of Northern European adults. 
 
METHODS 
Study samples 
Two population samples have been used in the current study: TwinsUK and Northern Finland Birth 
Cohort 1966 (NFBC1966). 
The TwinsUK register comprises female twin pairs recruited from the general UK population since 
1992 [27]. The twins have attended for lumbar MRI, nurse-led interview and collection of 
demographic data between 1996 and 2000 and lumbar MRI was performed for a subsample a decade 
later. The interview used a modified version of the UK Medical Research Council Back and Neck 
pain questionnaire and assessed a lifetime history of low back and neck pain, as well as psychological 
distress, lifestyle variables (e.g. physical exercise) and socioeconomic status, as described elsewhere 
[6]. Twins gave informed written consent and appropriate ethics permission had been obtained from 
the St Thomas’ Hospital Research Ethics Committee. Genotyping and imputation of the TwinsUK 
dataset was carried out as described previously [28]. Imputation was performed using 1000 Genomes 
phase 3 reference panel. The sample available for use in the current study had MC coded on MRI 
comprised 647 individuals including 625 females and 22 males. The sample mean age was 54.7±8.9 
years and mean BMI was 25.2±4.7 kgm-2.  
NFBC1966 comprises children born in Oulu and Lapland (Finland) who had expected dates of birth 
between Jan 1st and Dec 31st, 1966 (12,068 mothers, 12,231 children). Participants’ health, 
medication, healthcare utilisation, lifestyle habits and social status have been collected at ages 14, 31 
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and 46 years by questionnaire and a wide-scale health examination performed at 46 years. A subset 
of study subjects that had attended the examinations underwent lumbar MRI (n=1540). A total of 
5400 individuals were chosen for genotyping which was performed using Illumina Human CNV370-
Duo DNA bead chip as described previously [29]. The Ethical Committee of the Northern 
Ostrobothnia Hospital District has approved the study and the study subjects have given their 
informed written consent. The sample used for the current study comprised 1182 individuals 
including 642 females and 540 males. The mean age of the sample was 47.4±0.7 years and the mean 
BMI was 26.6±4.6 kgm-2.  
 
Magnetic resonance imaging and coding for MC 
In TwinsUK, the lumbar MRI at baseline and follow-up was performed using a 1.0-T equipment 
(Siemens, Munich, Germany) as previously reported [9]. In T2-weighted images a fast spin-echo 
sequence of time to recovery (TR) 5000–4500 ms and time to echo (TE) 112 ms, with a slice thickness 
of 4 mm were used. 
In NFBC1966, MRI was performed using a 1.5-T imaging system (Signa HDxt, General Electric, 
Milwaukee, Wisconsin, USA). The routine lumbar spine protocol was used with T2-weighted fast-
recovery fast spin-echo images in transverse and sagittal planes. In transverse planes time TE 118 ms 
and TR 4000 ms with slice thickness of 4 mm was used and in sagittal planes TE 112 ms and TR 
5000 ms with slice thickness of 3 mm was used. 
Coding for MC was carried out using standard methods in both TwinsUK and NFBC1966 by, or 
under the oversight of, co-author JM. In TwinsUK, a randomly chosen subset of the scans was re-
coded by the second observer (n=50). In NFBC1966, two observers coded all available scans in half 
and a subset of scans (n=66) was coded by both observers for the calculation of inter-rater reliability. 
Both rostral and caudal endplates were examined and the presence, type, height and width of MC 
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recorded as described previously [21]. MC was coded as type 1, type 1/2, type 2, type 2/3 and type 3 
in NFBC1966. In TwinsUK, the type of MC could not be fully assessed as only T2-weighted images 
had been obtained. In both cohorts, MC was measured by evaluating the maximum height and width 
of MC in rostral and caudal endplates. The maximum height of each MC was compared with the 
height of the vertebral body and coded as the following: 0) no MC; 1) MC in the endplate only; 2) 
MC height is less than 25% of the vertebral body; 3) MC height ranging from 25% to 50% of the 
vertebral body; and 4) MC height is more than 50% of the height of the vertebral body. The horizontal 
width of each MC was graded by dividing the vertebral body axially into four peripheral quadrants 
and one central circular zone with width ranging from 0 to 5. The mean (±SD) of the height grade of 
MC was 2.2±SD in NFBC1966 and 1.9±0.7 in TwinsUK, while the mean of the width grade of MC 
was 2.8±SD in NFBC1966 and 2.5±1.2 in TwinsUK. The inter-rater reliability for the presence of 
MC was kappa = 0.92 in TwinsUK; and kappa = 0.82 in NFBC1966.  
 
Genome-wide association study and meta-analysis 
For the GWAS, we did not stratify or filter out the subjects by the grade of MC; thus, the outcome 
phenotype was a categorical trait defined as the presence of MC regardless of the type or size of MC 
vs the absence of MC. Accordingly, the phenotype was coded as 1 (“MC of any type or size”) or 0 
(“no MC”). For NFBC1966, association analysis was carried out using SNPTEST v2.5.2, while for 
TwinsUK it was carried out using GEMMA v0.9. A linear regression model was fitted to test for 
additive effects of SNPs (genotype dosage) adjusting for age, sex, BMI, and either family relatedness 
via a kinship matrix (for TwinsUK) or population stratification using genotypic principal components 
(for NFBC1966). The use of linear regression for a categorical trait was dictated by the need to apply 
linear mixed-effects model for TwinsUK to account for family structure and the lack of statistical 
software that would allow such the analysis using logistic regression. Given that linear regression 
effect sizes are not straightforward to interpret in terms of the risks for categorical traits, we calculated 
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odds ratios (OR) and corresponding 95% confidence intervals (CI) using the following 
approximation: OR = exponent(β / (μ × (1 - μ))), where β is the linear effect size and μ is the case 
fraction in the dataset.  
Meta-analysis of the results obtained from NFBC1966 and TwinsUK samples was carried out by 
inverse-variance weighting approach using METAL software[30]. Prior to meta-analysis SNPs in 
both datasets were filtered out using the following settings: monomorphic SNP excluded; minor allele 
frequency < 0.03; deviation from Hardy-Weinberg equilibrium p-value < 1e-6 (to minimize the 
amount of SNPs with likely erroneous genotyping); genotyping call rate < 0.95; and imputation 
quality < 0.7. For NFBC1966 dataset, additionally we excluded SNPs for which model information 
estimated by SNPTEST was < 0.7. The total number of SNPs that were present in both datasets after 
applying the filters was 5,479,070.  
Genome-wide significance threshold was p < 5e-8; suggestive association thresholds were p < 5e-7 
and p < 1e-5. Post-GWAS analysis involved look-ups in the public databases including Phenoscanner 
[31], GTEx [32], LDlink [33], and RegulomeDB [34].  
In addition, we determined if SNPs associated with MC are also associated with chronic LBP 
(considered as pain between lowest rib and gluteal fold lasting 3 months or longer) in TwinsUK 
dataset (n = 4267) and acute or chronic BP (“Back pain” response to a question: “Pain type(s) 
experienced in last months”) using our ongoing study of UK Biobank (n = 453,862). 
 
RESULTS 
A total of 1829 individuals from two cohorts of Northern European ancestry (Finland and the UK) 
were examined by a GWAS meta-analysis. Overall, there were 994 individuals having MC detected 
by MRI (257 in TwinsUK and 737 in NFBC1966 cohorts) and 835 without MC (390 in TwinsUK 
and 445 in NFBC1966 cohorts).  
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In TwinsUK, a locus on chromosome 4 upstream SPOCK3 gene was found to be associated with MC, 
with the lead SNP rs72703315 (OR = 0.25, 95% CI = 0.15-0.40; p = 2.04e-08) (Supplementary Figure 
1, Supplementary Figure 2). In NFBC1966, a locus on chromosome 9 in intron of PTPRD gene was 
found to be associated with MC, with the lead SNP rs1934268 (OR = 1.79, 95% CI = 1.48-2.18; p = 
7.28e-09) (Supplementary Figure 3, Supplementary Figure 4). In both cohorts the test-statistic 
inflation (lambda) for the GWAS was 1.03 suggesting no significant population stratification. 
The results for SNPs with genome-wide significance (p<5e-8) and suggestive significance for 
association (p<5e-7) are listed in Table 1. Meta-analysis revealed a single locus on chromosome 9 
associated with MC with a genome-wide significance (Table 1, Figure 1, Figure 2). The test statistic 
inflation lambda = 1.02, suggesting no population stratification. The lead SNP rs1934268 was the 
same as that identified in the NFBC1966 cohort, located in an intron of the PTPRD gene which 
encodes a protein tyrosine phosphatase receptor type D (Figure 3). There was moderate heterogeneity 
between the studies for the lead SNP and suggestive SNPs in the region, though not statistically 
significant (p>0.05). The effect size of the association was rather high (for the lead SNP rs1934268, 
OR = 1.59, 95% CI = 1.36-1.86) suggesting a 59% increase in risk of MC for rs1934268*T allele vs 
rs1934268*C allele. This value was approximated from linear regression effect size so may be an 
overestimate. According to Phenoscanner, no associations have been reported for any other trait so 
far for the lead SNP rs1934268 or those in strong LD with it (r2>0.7). 
  
9 
 
Table 1. The results of meta-GWAS for Modic changes in TwinsUK and NFBC1966 cohorts.  
SNP ID 
Chr:Pos 
(hg19) 
Effec
t 
allele 
Othe
r 
allele 
EAF ± 
SE 
Beta ± 
SE 
OR (95% 
CI) 
P-value 
Directio
n I2 
Het. P-
value 
rs193426
8 
9:973036
6 T C 
0.788 ± 
0.032 
0.115 ± 
0.020 
1.59 (1.36-
1.86) 
7. 4E-
09 ++ 66.5 0.084 
rs438252
6 
9:972639
5 A G 
0.206 ± 
0.031 
-0.105 ± 
0.020 
0.66 (0.56-
0.77) 1.2E-07 -- 62.2 0.104 
rs704781
2 
9:972609
0 A C 
0.206 ± 
0.031 
-0.105 ± 
0.020 
0.66 (0.56-
0.77) 1.3E-07 -- 62.5 0.102 
rs786270
7 
9:972346
3 A G 
0.206 ± 
0.030 
-0.105 ± 
0.020 
0.66 (0.56-
0.77) 1.4E-07 -- 62.9 0.100 
rs589634
6 
9:970823
8 T TC 
0.793 ± 
0.030 
0.105 ± 
0.020 
1.53 (1.30-
1.79) 1.6E-07 ++ 57.2 0.126 
Chr:pos, chromosome:position; EAF, effect allele frequency; Beta, coefficient of linear regression 
for effect allele vs other allele; OR, Odds ratio calculated using the following approximation: OR = 
exp(β/(μ×(1-μ)), where μ is the prevalence of MC (0.54 in the joint dataset); I2, heterogeneity 
statistics.  
 
According to RegulomeDB, the rs1934268 SNP is located in the binding region for transcription 
factors BCL11A, SPI1 and PBX3 (Supplementary Figure 5), although the potential of this variant to 
affect binding is considered minimal (Regulome DB score = 5). The SNP is not known as an eQTL 
according to GTEx database. Moreover, no SNPs in high LD (r2>0.7) with the lead SNP are known 
to be functionally important according to LDlink and RegulomeDB. However, considering D’ as a 
measure of LD, a rare SNP rs186163656 in perfect LD with rs1934268 (D’ = 1) exhibits likely effect 
on the binding of CTCF transcription factor (RegulomeDB score = 2c) in an adjacent site. 
None of the other SNPs, apart from those on chromosome 9 at the PTPRD locus, achieved a strict 
suggestive significance threshold of 5e-7. However, 34 SNPs had p-values < 1e-5 which is considered 
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a threshold for suggestive association (Supplementary Table). These SNPs overlap or locate closely 
to the genes PTPRD, XKR4, SCIN, MGMT, DLG2, ZNF184, and OPRK1 with no heterogeneity 
between the studies in the majority of cases. 
We investigated whether the lead SNP rs1932568 is associated with back pain. In TwinsUK, the SNP 
was nominally associated with chronic LBP (OR = 1.26, 95%CI = 1.10-1.44; p = 0.001); however, 
in the much larger sample from UK Biobank, this association was not observed (OR = 1.00, 95% CI 
= 0.51-1.96; p = 0.914). 
DISCUSSION 
Using meta-analysis of two cohorts (TwinsUK and NFBC1966) with the total sample size of 1829, 
we identified a locus on chromosome 9 significantly associated with MC. While the lead SNP 
rs1934268 in the intron of PTPRD gene has not previously been associated with any trait, the 
association region is likely functional with at least one SNP (rs186163656) in strong LD with the lead 
SNP being able to affect binding of transcription factors. Transcription factor binding sites at or 
adjacent to the rs1934268 locus include SPI1, PBX3, BCL11A and CTCF. SPI1 participates in 
regulation of osteoclast differentiation [35]. CTCF and PBX3 are involved in multiple pathways 
including regulation of homeodomain proteins during the development of embryonic anterior-
posterior axis and limb buds [36,37], while BCL11A participates in spinal cord development [38]. 
These data suggest that the activity of PTPRD may be affected by genetic variants in the site via 
influence on the binding of a number of transcription factors during bone growth and embryonic 
development of the musculoskeletal system.  
The PTPRD gene encodes protein tyrosine phosphatase receptor type D, a member of the protein 
tyrosine phosphatase (PTP) family that is involved in controlling a variety of cellular processes 
including cell growth, differentiation, mitotic cycle and oncogenic transformation. It is critically 
important for neural system development via promoting neurite growth and axon guidance [39] and 
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it also acts as a tumour suppressor [40]. According to GTEx database, the gene is highly expressed 
in brain tissues including spinal cord. More importantly in the context of MC, the gene is 
overexpressed in intact cartilage as compared with damaged osteoarthritic cartilage [41], and its 
expression is associated with clinical success after autologous chondrocyte implantation [42]. 
Furthermore, in mice, homologues Ptprd gene was found to be expressed in vertebral cartilage 
condensation during spinal development 
(http://www.informatics.jax.org/tissue/marker/MGI:97812). Also, the PTPN11 gene, another 
member of the PTP family, was established to play a critical role in cartilage development and 
homeostasis [43]. Thus, PTPRD gene appears to be a functionally plausible candidate gene for the 
development of MC. Interestingly, in TwinsUK, the direction of the effect of the SNP on MC and 
chronic LBP are consistent with the T allele predisposing to the higher risk of both MC and chronic 
LBP. This is concordant with a hypothesis of MC as a risk factor for LBP and provides evidence of 
underlying molecular factors [44].  
Of the suggestive associations identified in the current study (Supplementary table 1), OPRK1 is of 
particular interest. Even though the signal for this gene was not seen independently in two 
participating cohorts, it is remarkably more significant in the meta-analysis and shows no 
heterogeneity between the studies, thus indicating a strong trend towards replication. According to 
the GTEx, all the SNPs near OPRK1 with suggestive association with MC (Supplementary Table) 
are eQTLs for this gene. The protein encoded by the gene is an opioid receptor involved in pain 
perception and variation in its expression is observed in the lumbar spinal cord in neuropathic pain 
model [45]. Moreover, it is highly expressed in prechondrocytes and involved in protection against 
degradation in injured cartilaginous tissues [46].  
To our knowledge, this is the first ever GWAS reported for MC. Identifying the genetic factors 
contributing to MC increases our knowledge of the etiology and pathology of this trait, which might 
in future lead to identification of novel biomarkers or therapeutic targets for LBP and intervertebral 
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disc degeneration. As a GWAS study, the results allow limited interpretation at this stage, owing to 
the lack of available functional data on human disc such as eQTL or chromatin features. However, if 
we are to move the field forward, a whole range of techniques, including genetic ones, will need to 
be brought to bear. These results are an important first step and that the genetic loci identified may 
offer a highly relevant pointer to mechanisms of pathogenesis in MC leading to LBP. 
The study has limitations. The sample size was not high according to the state-of-the art requirements 
for GWAS; however, this was dictated by the availability of cohorts having costly spine MR imaging 
with MC coded using the same methods, as well as genome-wide genotypes in ethnically similar 
samples. Replication in other datasets is needed to validate our findings further. Furthermore, 
functional experimental studies are required to assess the impact of PTPRD on the development of 
MC. Both replication and functional validation are necessary to ensure that our finding is not false-
positive. These issues are not specific to our study and are common for complex traits GWAS. It is 
apparent that the significant association in the meta-analysis was driven by NFBC1966 cohort and a 
single significant locus present in TwinsUK on chromosome 4 was not reproduced in the meta-
analysis. There was also a heterogeneity between the cohorts. The prevalence of MC in TwinsUK 
and NFBC1966 was different (39.7% and 62.3%, respectively) likely reflecting samples differing in 
mean age and sex ratio, both factors being known to be contribute to the risk of MC [20]. Also, 
different MRI equipment and field-strengths were used in NFBC1966 and TwinsUK for unavoidable 
reasons. A 1.5-T equipment was used in NFBC1966 and 1.0-T equipment in TwinsUK. 1.5-T 
indicates that the field strength is 1.5 tesla whereas 1.0-T equipment has a magnetic field of 1.0 tesla. 
This theoretically could have impacted the MC evaluation - MC is more often observed in higher-
field MRI [47]. This is unlikely, though, given that the difference in the magnetic field strengths is 
not great at 0.5T. 
TwinsUK, despite being older on average than NFBC1966, exhibited lower prevalence of MC, so the 
higher number of males in NFBC1966 may explain the difference in the prevalence of MC. To 
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address this, we tested chromosome 4 and 9 loci for gender-specific effects in NFBC1966 (impractical 
in TwinsUK as males n = 22). In this stratified analysis, there was no association between MC and 
the lead SNP on chromosome 4 (OR = 0.99, 95% CI = 0.58-1.69, p = 0.9774; OR = 1.01, 95% CI = 
0.62-1.65, p = 0.9647, in men and women respectively). However, there was a significant 
unidirectional association between MC and the lead SNP on chromosome 9 in males and females 
(OR = 1.96, 95% CI = 1.48-2.61, p = 2.13e-6; OR = 1.71, 95% CI = 1.30-2.25, p = 1.24e-4, 
respectively).  
It seems unlikely, therefore, that the association with the chromosome 9 region is gender-specific, 
while the difference between the results in TwinsUK and NFBC1966 for chromosome 4 region may 
reflect other differences not measured between the cohorts, such as ethnic specificity in MC 
prevalence and gene-environmental interactions. While MC has been shown in both small clinical 
and large epidemiological studies to be an independent risk factor for LBP, we did not find any 
association between rs1934268 and BP in the very large UK Biobank sample. This suggests perhaps 
that in the general population represented by the UK Biobank participants, MC-mediated BP does not 
contribute a large enough genetic signal to be detectable amongst all the other causes of BP. Further 
work should, therefore, concentrate on the aetiology of MC and more specific subgroup GWAS 
analysis performed in chronic LBP.  
In summary, our GWAS meta-analysis for MC provides evidence of genetic contribution to the 
development of this trait and identifies novel candidate genes. Further functional studies may provide 
insight into the genesis of this trait and, eventually, clarify the role of MC in LBP.  
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FIGURE LEGENDS 
Figure 1. Manhattan plot for the meta-analysis of GWAS of Modic changes in Northern 
European populations (Finland and UK, total N = 1829).  Manhattan plot depicts p-values (-log10) 
presented on the y-axis and chromosomal position on the x-axis. Solid line depicts genome-wide 
significance (5e-8); dashed line depicts suggestive significance (5e-7).  
 
Figure 2. Quantile-quantile plot for the meta-analysis of GWAS of Modic changes in Northern 
European populations (Finland and UK, total N = 1829). The Q-Q plot depicts the observed p-
values against the expected p-values on -log10-scale. The test-statistic inflation (lambda) was 1.02, 
suggesting absence of population stratification in the dataset. 
 
Figure 3. Regional association plot of PTPRD locus. The association p-value (-log10) is represented 
on the left-hand y-axis, recombination rate is displayed on the right-hand y-axis. Genomic location is 
shown on the x-axis (GRCh37/hg19). RefSeq genes are indicated in the bottom panel. Linkage 
disequilibrium r2 relative to the index single nucleotide variant rs1934268 (marked with diamond) is 
shown using the colors in the figure legend. 
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Supplementary table - The results of meta-GWAS for Modic changes in TwinsUK and NFBC1966 cohorts for SNPs with p-value 5e-7 < P 
< 1e-5 
SNP ID Chr:Pos Effect 
allele 
Other 
allele 
EAF ± SE Beta ± SE OR (95% CI) P-value Direction I2 Het. P-
value 
Overlapped 
gene 
Nearest gene 
(upstream or 
downstream) 
rs36160095 4:32845987 A G 0.938 ± 0.003 0.156 ± 0.034 1.87 (1.43-2.45) 3.4E-06 ++ 0 0.510 - - 
rs140476053 4:32843085 C G 0.938 ± 0.003 0.155 ± 0.034 1.87 (1.43-2.44) 3.7E-06 ++ 0 0.522 - - 
rs143907932 4:32847206 T C 0.062 ± 0.002 -0.155 ± 0.034 0.54 (0.41-0.7) 4.0E-06 -- 0 0.528 - - 
rs150196231 4:32844355 T C 0.063 ± 0.004 -0.151 ± 0.034 0.54 (0.42-0.71) 6.6E-06 -- 0 0.634 - - 
rs201475493 6:27455134 A AAATG 0.073 ± 0.010 -0.143 ± 0.031 0.56 (0.44-0.72) 3.0E-06 -- 0 0.762 - ZNF184 
rs150644047 6:27457523 T C 0.073 ± 0.010 -0.141 ± 0.031 0.57 (0.44-0.72) 4.2E-06 -- 0 0.806 - ZNF184 
rs16867808 6:27463684 T C 0.928 ± 0.010 0.142 ± 0.031 1.77 (1.39-2.26) 4.2E-06 ++ 0 0.807 - ZNF184 
rs78950897 6:27471298 T G 0.072 ± 0.010 -0.142 ± 0.031 0.56 (0.44-0.72) 4.3E-06 -- 0 0.809 - ZNF184 
rs74293985 6:27472488 T C 0.928 ± 0.010 0.142 ± 0.031 1.77 (1.39-2.26) 4.3E-06 ++ 0 0.809 - ZNF184 
rs77052921 6:27473455 A C 0.928 ± 0.010 0.142 ± 0.031 1.77 (1.39-2.26) 4.3E-06 ++ 0 0.810 - ZNF184 
rs77380993 6:27474646 T C 0.928 ± 0.010 0.142 ± 0.031 1.77 (1.39-2.26) 4.3E-06 ++ 0 0.810 - ZNF184 
rs80183551 6:27454446 A G 0.928 ± 0.010 0.141 ± 0.031 1.76 (1.38-2.25) 4.4E-06 ++ 0 0.820 - ZNF184 
rs76458558 6:27480547 A G 0.928 ± 0.010 0.138 ± 0.031 1.74 (1.36-2.23) 7.9E-06 ++ 0 0.997 - ZNF184 
rs1017404 7:12695507 A G 0.783 ± 0.015 0.088 ± 0.019 1.43 (1.23-1.66) 3.9E-06 ++ 53.2 0.144 - - 
rs1036372 7:12695169 A G 0.783 ± 0.015 0.088 ± 0.019 1.43 (1.23-1.66) 4.0E-06 ++ 55.2 0.135 - - 
rs6473810 8:54244458 A G 0.682 ± 0.002 -0.078 ± 0.017 0.73 (0.64-0.84) 4.6E-06 -- 0 0.731 - OPRK1 
rs7831674 8:54224521 A T 0.683 ± 0.001 -0.078 ± 0.017 0.73 (0.64-0.84) 4.9E-06 -- 0 0.703 - OPRK1 
rs10107460 8:54247311 A G 0.681 ± 0.003 -0.077 ± 0.017 0.73 (0.64-0.84) 4.9E-06 -- 0 0.716 - OPRK1 
rs2658912 8:56280631 A G 0.127 ± 0.015 -0.106 ± 0.024 0.65 (0.54-0.79) 9.1E-06 -- 0 0.869 XKR4 - 
rs1174582 9:9763539 C G 0.821 ± 0.037 0.104 ± 0.022 1.52 (1.28-1.81) 1.2E-06 ++ 0 0.552 PTPRD - 
rs2761762 9:9733974 A G 0.768 ± 0.044 0.089 ± 0.019 1.43 (1.23-1.66) 3.2E-06 ++ 0 0.337 PTPRD - 
rs4742607 9:9513109 A G 0.462 ± 0.043 -0.071 ± 0.016 0.75 (0.66-0.85) 9.3E-06 -- 0 0.635 PTPRD - 
rs4742606 9:9513039 A G 0.462 ± 0.043 -0.071 ± 0.016 0.75 (0.66-0.85) 9.4E-06 -- 0 0.634 PTPRD - 
rs1174587 9:9767971 A G 0.829 ± 0.036 0.097 ± 0.022 1.48 (1.24-1.76) 9. 5E-06 ++ 0 0.524 PTPRD - 
rs74778840 10:131489527 C G 0.902 ± 0.039 -0.131 ± 0.030 0.59 (0.47-0.75) 8.8E-06 -- 0 0.792 MGMT - 
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rs117285296 11:83055365 A G 0.153 ± 0.028 0.110 ± 0.022 1.56 (1.31-1.85) 8.2E-07 ++ 0 0.329 - - 
rs2043208 11:83184839 A G 0.235 ± 0.029 0.084 ± 0.019 1.4 (1.21-1.63) 6.5E-06 ++ 0 0.913 DLG2 - 
rs9787813 11:83184256 A C 0.229 ± 0.030 0.084 ± 0.019 1.4 (1.21-1.63) 8.1E-06 ++ 0 0.783 DLG2 - 
rs183727937 11:83178853 T C 0.650 ± 0.038 -0.076 ± 0.017 0.74 (0.64-0.84) 8.4E-06 -- 0 0.409 DLG2 - 
rs57023373 11:83181164 T G 0.319 ± 0.028 0.076 ± 0.017 1.36 (1.19-1.55) 9.5E-06 ++ 0 0.492 DLG2 - 
rs143569491 11:83195804 T TG 0.230 ± 0.031 0.084 ± 0.019 1.4 (1.21-1.63) 9.8E-06 ++ 0 0.864 DLG2 - 
rs17461216 11:83193813 A G 0.230 ± 0.031 0.084 ± 0.019 1.4 (1.21-1.63) 9.8E-06 ++ 0 0.864 DLG2 - 
rs1432050 11:83201563 T C 0.229 ± 0.032 0.084 ± 0.019 1.4 (1.21-1.63) 9.9E-06 ++ 0 0.873 DLG2 - 
 
Table legend 
Genome-wide association study for Modic changes was carried out separately in TwinsUK and NFBC1966 cohorts followed by meta-analysis 
using inverse-variance weighting approach. Chr:pos, chromosome:position; EAF, effect allele frequency; Beta, coefficient of linear regression for 
effect allele vs other allele; OR, Odds ratio calculated using the following approximation: OR = exp(Beta/(μ×(1-μ)), where μ is the prevalence of 
MC (0.54 in the merged dataset); I2, heterogeneity statistics. 
 
 
 
 
 
